Dyadic International recorded first direct commercial product sales; management also cited substantial doubt about its ability to continue as a going concern.
DYAI · Dyadic International Inc
Substantial doubt about the company's ability to continue as a going concern.
“Management concluded that the net proceeds of the August 2026 offering, which are included in our cash and investment securities at September 30, 2026, do not alleviate substantial doubt about our ability to continue as a going concern. The Company believes that substantial doubt exists regarding its ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.31
- Open
- $0.32
- Day range
- $0.30–0.34
- 52-week closing range
- $0.31–1.47
- Average volume, 30 days
- 92K
- Short interest
- 83K · 0.2% of shares · 1.0 days
- Short volume, last session
- 68%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 13
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Dyadic International, Inc. recorded its first direct commercial protein sales in the quarter ended September 30, 2026, while revenue fell 61.4% to $449,101. Net loss was $1,357,041, and its cash position was $6,046,083 as of September 30, 2026.
Revenue was approximately $449,000, down 61%, with loss of approximately $1.4 million ($0.04 per share) and about $6 million in cash. Dyadic booked first direct protein sales and expects a $225,000 payment in the fourth quarter from Enzymes' chymosin sale.
Dyadic International received Nasdaq deficiency notices for failing the minimum $1 per share bid price and $35 million Market Value of Listed Securities requirements. It has until March 24, 2027 to regain compliance, and may appeal any delisting determination.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Commercial and technical milestones included first direct protein sales, expanded distribution, a $225,000 chymosin milestone, advancing alpha-lactalbumin collaboration, and rapid C1 antibody and vaccine development results. However, revenue fell 61.4%, cash declined to $6,046,083, operating cash burn remained approximately $5.3 million for nine months, commercial sales remained modest, and management disclosed going-concern uncertainty.
- + Dyadic recorded its first direct commercial protein product sales and expanded third-party distribution.
- + Inzymes achieved the first commercial sale of the second Dapibus-produced chymosin, triggering a $225,000 milestone payment expected as fourth-quarter revenue.
- + C1 achieved antibody yields of approximately 12.1 g/L for RSV and 13.2 g/L for malaria.
- + C1 produced two ebolavirus antigens in approximately 15 days and a monoclonal antibody in approximately seven weeks.
- + The BRIG BIO and Strive Nutrition collaboration is advancing bovine alpha-lactalbumin toward potential commercial-scale supply.
- + Quarterly net loss narrowed to approximately $1.4 million, or $0.04 per share, from approximately $2 million, or $0.06 per share.
- − Third-quarter revenue fell 61.4% to $449,101 from $1,164,617 year over year.
- − Cash, restricted cash, and investment-grade securities declined to $6,046,083 from $8,587,289.
- − Net cash used in operating activities was approximately $5.3 million for the first nine months, and management expects similar cash usage.
- − Management disclosed substantial doubt about the company's ability to continue as a going concern.
- − Early commercial sales remained modest and evaluation timelines were longer than anticipated.
- − Limited capital has constrained inventory placement and slowed the research product business.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| from plasmid to C-tag-purified protein | 15 | third quarter | — |
| production yields of approximately 12.1 g/L for RSV monoclonal antibody RSM01 | 12.1 | third quarter | — |
| production yields of approximately 12.1 g/L for RSV monoclonal antibody RSM01 and 13.2 g/L for m | 13.2 | third quarter | — |
| Pilot-scale process improvements increased recombinant human transferrin productivity | 80% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYAI
this stock
Dyadic International Inc
|
$12.46M | -66.9% | -11.6% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 22
Dyadic International, Inc. recorded its first direct commercial protein sales in the quarter ended September 30, 2026, while revenue fell 61.4% to $449,101. Net loss was $1,357,041, and its cash position was $6,046,083 as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYAI | -11.2% | -22.7% | -60.2% | -18.3% | -66.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -5.8% | -16.4% | -54.5% | -13.0% | -71.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.